STOCK TITAN

CNBX Patent Application "Composition and Method for Treating Cancer with Cannabinoids" Enters National Phase in US and Israel

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

CNBX Pharmaceuticals has announced the filing of a patent application entitled "COMPOSITION AND METHOD FOR TREATING CANCER WITH CANNABINOIDS" with the US Patent and Trademark Office and the Israel Patent Office on October 12, 2022. This application is related to drug candidates in its pipeline, including CNBX RCC-33, targeting colorectal cancer. The company has an extensive IP portfolio of 8 patent families, with 7 granted patents and 18 pending, focusing on innovative cancer treatments.

Positive
  • Filing of a new patent application can strengthen CNBX's intellectual property portfolio, potentially enhancing its market position.
  • The company is advancing drug candidates towards clinical trials, specifically the CNBX RCC-33 drug for colorectal cancer.
Negative
  • None.

REHOVOT, Israel and BETHESDA, Md., Oct. 13, 2022 /PRNewswire/ - CNBX Pharmaceuticals Inc. (OTC-QB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that the Company's patent application titled "COMPOSITION AND METHOD FOR TREATING CANCER WITH CANNABINOIDS" was filed on October 12, 2022 with the US Patent and Trademark Office (USPTO) and with the Israel Patent Office under a national phase of International Patent Application. National phase filing in Europe will follow.

CNBX Pharmaceuticals Logo

Said patent application relates to several of the drug candidates on the Company's pipeline for the treatment of various types of cancer, including CNBX RCC-33, for the treatment of colorectal cancer currently being developed and prepared for a pre-IND meeting with the FDA and a first-in-human Phase I/II(a) validation study.

The company's growing IP portfolio includes 8 patent families, with 7 granted patents and 18 additional pending. The company's IP portfolio is focused on cancer patients and cancer treatments, and includes claims relating to Pharmaceutical Compositions, Methods and Systems.

Recent News:

About CNBX Pharmaceuticals:

CNBX Pharmaceuticals Inc. (OTC-QB: CNBX) is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit www.cnbxpharma.com. For the latest updates on CNBX Pharmaceuticals follow the Company on Twitter@cnbxpharma, Facebook@cnbxPharmaceuticals, LinkedIn https://www.linkedin.com/company/cnbx, and on Instagram @CNBX_Pharmaceuticals.

Disclaimer:

Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our Company's management and are subject to significant risks and uncertainties. Actual results may differ from those outlined in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission including, without limitation, our latest 10-Q Report filed July 14th, 2022. We undertake no duty to update any forward-looking statement or any information contained in this press release or other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc., which are condoned by the Company, must emanate from the Company itself and bear our name as its source.

For more information about CNBX:

CNBX Pharmaceuticals Inc.
+1 (877) 424-2429
info@cnbxpharma.com
https://www.cnbxpharma.com

Logo: https://mma.prnewswire.com/media/1774404/CNBX_Pharmaceuticals_Logo.jpg

Cision View original content:https://www.prnewswire.com/news-releases/cnbx-patent-application-composition-and-method-for-treating-cancer-with-cannabinoids-enters-national-phase-in-us-and-israel-301648446.html

SOURCE CNBX Pharmaceuticals Inc.

FAQ

What is the recent patent application filed by CNBX Pharmaceuticals?

CNBX Pharmaceuticals filed a patent application titled "COMPOSITION AND METHOD FOR TREATING CANCER WITH CANNABINOIDS" on October 12, 2022.

What drug candidate is CNBX Pharmaceuticals developing for colorectal cancer?

CNBX Pharmaceuticals is developing CNBX RCC-33 for the treatment of colorectal cancer.

How many patents does CNBX Pharmaceuticals currently have?

CNBX Pharmaceuticals has a total of 8 patent families, with 7 granted patents and 18 pending.

When was the patent application filed by CNBX Pharmaceuticals?

The patent application was filed on October 12, 2022.

What is the focus of CNBX Pharmaceuticals' research and development?

CNBX Pharmaceuticals focuses on cannabinoid-based medicine for cancer treatments.

CNBX PHARMACEUTICAL INC

OTC:CNBX

CNBX Rankings

CNBX Latest News

CNBX Stock Data

463.56k
27.07M
10.67%
Biotechnology
Healthcare
Link
United States of America
Bethesda